keyword
MENU ▼
Read by QxMD icon Read
search

vonoprazan

keyword
https://www.readbyqxmd.com/read/29337157/update-on-use-of-vonoprazan-a-competitive-acid-blocker-p-cab
#1
EDITORIAL
David Y Graham, Maria Pina Dore
No abstract text is available yet for this article.
January 11, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29282636/vonoprazan-a-novel-and-potent-alternative-in-the%C3%A2-treatment-of-acid-related-diseases
#2
REVIEW
Xiaoxiao Yang, Yueyue Li, Yiyuan Sun, Mingming Zhang, Chuanguo Guo, Iqtida Ahmed Mirza, Yan-Qing Li
Although proton pump inhibitors (PPIs) have been used widely, acid-related diseases are still associated with a huge burden on the health care system. Recently, the efficacy and safety of a new acid suppressant named vonoprazan in the treatment of acid-related diseases have been evaluated by a series of studies. As a novel potassium-competitive acid blocker, vonoprazan may provide reversible acid suppression by preventing K+ from binding to gastric H+/K+-ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H...
December 27, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29278655/eosinophilic-esophagitis-in-japan-focus-on-response-to-acid-suppressive-therapy
#3
REVIEW
Norihisa Ishimura, Yoshikazu Kinoshita
Eosinophilic esophagitis (EoE) is a chronic inflammatory condition characterized by esophageal dysfunction and dense eosinophilic infiltration of esophageal epithelium. According to clinical consensus and guidelines published in 2011, esophageal eosinophilia was classified into 2 entities based on response to proton pump inhibitor (PPI) administration; EoE and PPI-responsive esophageal eosinophilia (PPI-REE). We have performed a series of investigations to determine whether EoE is actually different from PPI-REE...
December 26, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29215611/parietal-cell-protrusions-and-dilated-oxyntic-glands-from-use-of-vonoprazan
#4
Shuichi Miyamoto, Yoshihiro Matsuno, Mototsugu Kato, Takahiko Kudo, Shouko Ono, Yuichi Shimizu, Naoya Sakamoto
No abstract text is available yet for this article.
December 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29214885/short-term-efficacy-of-potassium-competitive-acid-blocker-following-gastric-endoscopic-submucosal-dissection-a-propensity-score-analysis
#5
Yohei Horikawa, Hiroya Mizutamari, Nobuya Mimori, Yuhei Kato, Saki Fushimi, Sayaka Sato, Syunji Okubo
BACKGROUND: Endoscopic submucosal dissection (ESD) is a promising method for the resection of superficial gastric neoplasms. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that is currently considered as a potential alternative to proton pump inhibitors (PPIs) for the treatment of acid-related diseases. However, the utility of vonoprazan in ESD-related ulcers is unclear. Therefore, we compared the short-term efficacies of vonoprazan and the PPI lansoprazole in ESD-related ulcer healing during the first two weeks following intervention...
December 7, 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/29208676/vonoprazan-aspirin-and-nsaids-new-era-in-acid-inhibition-and-gastroprotection
#6
EDITORIAL
Ali S Taha
No abstract text is available yet for this article.
December 5, 2017: Gut
https://www.readbyqxmd.com/read/29196436/vonoprazan-prevents-low-dose-aspirin-associated-ulcer-recurrence-randomised-phase-3-study
#7
Takashi Kawai, Kazunori Oda, Nobuo Funao, Akira Nishimura, Yasushi Matsumoto, Yuji Mizokami, Kiyoshi Ashida, Kentaro Sugano
OBJECTIVE: Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study. DESIGN: Double-blind, randomised, non-inferiority study; single-blind extension study at 104 Japanese sites, including 621 patients (439 in extension) with a history of peptic ulcers who required long-term LDA therapy. Randomised (1:1:1, computer generated) patients received lansoprazole 15 mg (n=217), vonoprazan 10 mg (n=202) or vonoprazan 20 mg (n=202) once daily for 24 weeks (double blind) and ≤2 years (extension)...
December 1, 2017: Gut
https://www.readbyqxmd.com/read/29181022/first-line-helicobacter-pylori-eradication-with-vonoprazan-clarithromycin-and-metronidazole-in-patients-allergic-to-penicillin
#8
Soichiro Sue, Nobumi Suzuki, Wataru Shibata, Tomohiko Sasaki, Hiroaki Yamada, Hiroaki Kaneko, Toshihide Tamura, Tomohiro Ishii, Masaaki Kondo, Shin Maeda
Aim: To assess the efficacy of 7-day first-line Helicobacter pylori eradication with vonoprazan (VPZ), clarithromycin (CAM), and metronidazole (MNZ) in patients with penicillin allergy. Methods: Patients with penicillin allergy, diagnosed with Helicobacter pylori infection and did not have history of Helicobacter pylori eradication, were eligible for the study. Twenty patients were prospectively treated with 20 mg VPZ twice daily, 200 or 400 mg CAM twice daily, and 250 mg MNZ twice daily for 7 days...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/29180359/tegoprazan-a-novel-potassium-competitive-acid-blocker-to-control-gastric-acid-secretion-and-motility
#9
Nobuyuki Takahashi, Yukinori Take
Tegoprazan, (S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide, a potassium-competitive acid blocker (P-CAB), is a novel potent and highly selective inhibitor of gastric H+/K+-ATPase. Tegoprazan inhibited porcine, canine, and human H+/K+-ATPases in vitro with IC50 values ranging 0.29 ~ 0.52 μM while that for canine kidney Na+/K+-ATPase was more than 100 μM. A kinetic analysis revealed that tegoprazan inhibited H+/K+-ATPase with potassium-competitive manner and the binding was reversible...
November 27, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/29142181/treatment-strategy-for-standard-dose-proton-pump-inhibitor-resistant-reflux-esophagitis
#10
Katsuhiko Iwakiri
Reflux esophagitis is characterized by excessive esophageal acid exposure. To treat reflux esophagitis, it is necessary to reduce excessive esophageal acid exposure to within the normal range. The first-line drug for the treatment of reflux esophagitis is a standard-dose proton-pump inhibitor (PPI), which is also recommended by the Evidence-based Clinical Practice Guidelines 2015 for gastroesophageal disease of the Japanese Society of Gastroenterology. It has been reported that the response to a standard dose of PPI in patients with mild reflux esophagitis is 90-100%, and that in patients with severe reflux esophagitis is 80-85%...
2017: Journal of Nippon Medical School, Nippon Ika Daigaku Zasshi
https://www.readbyqxmd.com/read/29132551/vonoprazan-treatment-improves-gastrointestinal-symptoms-in-patients-with-gastroesophageal-reflux-disease
#11
Satoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, Hirotsugu Sakamoto, Yoshimasa Miura, Alan Kawarai Lefor, Hironori Yamamoto
The effects of vonoprazan, a new potassium-competitive acid blocker, on gastroesophageal reflux disease (GERD) symptom are not fully elucidated. The aim of this study is to determine the effect of vonoprazan on GERD and associated gastrointestinal symptoms. We retrospectively reviewed 88 Helicobacter pylori negative patients with GERD treated with vonoprazan 10 mg daily. Symptoms were evaluated using the Izumo scale, which reflects quality of life related to various abdominal symptoms. The rates of improvement and resolution of GERD symptoms were 86% (76/88) and 57% (50/88), respectively...
December 2017: Kaohsiung Journal of Medical Sciences
https://www.readbyqxmd.com/read/29112902/development-of-a-stability-indicating-hplc-method-for-simultaneous-determination-of-ten-related-substances-in-vonoprazan-fumarate-drug-substance
#12
Zhiqiang Luo, Aoxue Liu, Yang Liu, Guopeng Wang, Xinjing Chen, Hao Wang, Mengwei Li, Haili Zhang, Yanhua Qiu, Huaqiang Zhai
Vonoprazan fumarate is a novel potassium-competitive acid blocker for the treatment of acid-related diseases. In the present study, a simple, fast, and economic reversed-phase liquid chromatography (LC) method was developed for the analysis of ten related substances (raw materials, by-products and degradants) in vonoprazan fumarate. The optimized separation was performed on a Phenomenex Kinetex EVO C18 (250mm×4.6mm, 5.0μm) column. The mobile phase consisted of (A) 0.03M sodium phosphate buffer (pH adjusted to 6...
November 4, 2017: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29057719/changes-in-gefitinib-erlotinib-and-osimertinib-pharmacokinetics-under-various-gastric-ph-levels-following-oral-administration-of-omeprazole-and-vonoprazan-in-rats
#13
Osamu Yasumuro, Shinya Uchida, Yasuharu Kashiwagura, Ayae Suzuki, Shimako Tanaka, Naoki Inui, Hiroshi Watanabe, Noriyuki Namiki
1. Although drug interactions between epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and gastric acid-suppressing medications (AS) are considered clinically significant, there is limited data regarding the influence of various gastric pH conditions on the pharmacokinetics of EGFR-TKIs. We aimed to clarify the changes in the pharmacokinetics of the EGFR-TKIs, gefitinib, erlotinib, and osimertinib, due to the changes in gastric pH after administration of omeprazole or vonoprazan. 2. Omeprazole (10 - 100 mg/kg, p...
October 21, 2017: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/28988197/vonoprazan-prevents-ulcer-recurrence-during-long-term-nsaid-therapy-randomised-lansoprazole-controlled-non-inferiority-and-single-blind-extension-study
#14
Yuji Mizokami, Kazunori Oda, Nobuo Funao, Akira Nishimura, Satoshi Soen, Takashi Kawai, Kiyoshi Ashida, Kentaro Sugano
OBJECTIVE: To assess the non-inferiority of vonoprazan to lansoprazole for secondary prevention of non-steroidal anti-inflammatory drug (NSAID)-induced peptic ulcer (PU) and the safety of vonoprazan during extended use. DESIGN: A phase 3, 24-week, multicenter, randomised, double-blind (DB), active-controlled study, followed by a phase 3, ≥28 week, multicenter, single-blind, parallel-group extension study (EXT) in outpatients (n=642) receiving long-term NSAID therapy who are at risk of PU recurrence...
October 7, 2017: Gut
https://www.readbyqxmd.com/read/28986609/comparison-of-effect-of-an-increased-dosage-of-vonoprazan-versus-vonoprazan-plus-lafutidine-on-gastric-acid-inhibition-and-serum-gastrin
#15
Takahiro Suzuki, Takuma Kagami, Takahiro Uotani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, Takahisa Furuta
BACKGROUND: Vonoprazan, a novel potassium-competitive acid blocker, elicits potent acid inhibition and hypergastrinemia at a dose of 20 mg. Its recommended maintenance dose for gastro-esophageal reflux disease is 10 mg, which is sometimes insufficient for preventing nocturnal acid breakthrough (NAB). Concomitant use of a histamine 2 receptor antagonist (H2RA) is effective for NAB. However, further acid inhibition by addition of H2RA has concern of hypergastrinemia again. Lafutidine (H2RA) is known to stimulate somatostatin release...
October 6, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28894571/vonoprazan-10-mg-daily-is-effective-for-the-treatment-of-patients-with-proton-pump-inhibitor-resistant-gastroesophageal-reflux-disease
#16
Satoshi Shinozaki, Hiroyuki Osawa, Yoshikazu Hayashi, Hirotsugu Sakamoto, Yasutoshi Kobayashi, Alan Kawarai Lefor, Hironori Yamamoto
Gastroesophageal reflux disease (GERD) is commonly treated by primary care physicians. Although proton pump inhibitors (PPI) have been the mainstay of GERD treatment for two decades, in some patients GERD is refractory to standard dose PPI for more than eight weeks and is referred to as PPI-resistant GERD. Vonoprazan, a novel competitive acid blocker, became available in Japan for the treatment of patients with GERD, and has greater acid inhibition than existing PPIs. The aim of the present study was to determine the effect of vonoprazan 10 mg daily on PPI-resistant GERD...
September 2017: Biomedical Reports
https://www.readbyqxmd.com/read/28891137/treatment-of-helicobacter-pylori-infection-2017
#17
REVIEW
Anthony O'Connor, Dominique Lamarque, Javier P Gisbert, Colm O'Morain
This review summarizes important studies regarding Helicobacter pylori therapy published from April 2016 to April 2017. The main themes that emerge involve studies assessing the efficacy of bismuth and nonbismuth quadruple regimens. While in recent years, much of the emphasis on the use of bismuth has focussed on its utility in a second-line setting, an increasing number of studies this year have shown excellent efficacy in first-line therapy. The efficacy of bismuth as a second-line after sequential and concomitant therapy was particularly noteworthy...
September 2017: Helicobacter
https://www.readbyqxmd.com/read/28884937/a-japanese-population-based-meta-analysis-of-vonoprazan-versus-ppi-for-helicobacter-pylori-eradication-therapy-is-superiority-an-illusion
#18
REVIEW
Shou Quan Dong, Tikka Prabhjot Singh, Xin Wei, Huang Yao, Hong Ling Wang
BACKGROUND: Vonoprazan (VPZ) is a novel acid suppressant that has been used in Helicobacter pylori (H. pylori) eradication therapies in recent years. However, the efficacy and safety of VPZ vs proton-pump inhibitor (PPI) in H. pylori eradication therapies remain controversial. OBJECTIVE: To perform a meta-analysis in order to assess the efficacy and safety of VPZ vs PPI for H. pylori eradication. MATERIALS AND METHODS: The PubMed, EMBASE, and Cochrane Library databases were searched up to July 10, 2017, for relevant randomized controlled trials (RCTs) and nonrandomized clinical studies (NRCTs)...
September 8, 2017: Helicobacter
https://www.readbyqxmd.com/read/28875498/comparative-study-of-effects-of-vonoprazan-and-esomeprazole-on-antiplatelet-function-of-clopidogrel-or-prasugrel-in-relation-to-cyp2c19-genotype
#19
Takuma Kagami, Mihoko Yamade, Takahiro Suzuki, Takahiro Uotani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Kazuo Umemura, Hiroaki Miyajima, Takahisa Furuta
Drug-drug interaction between antiacid and antiplatelet agents has not been fully elucidated. Vonoprazan, a new potassium competitive acid blocker, has been available in Japan. CYP2C19 and CYP3A4 are involved in the metabolism of clopidogrel, prasugrel, esomeprazole, and vonoprazan. Using a P2Y12 assay, we compared the effects of vonoprazan and esomeprazole on the antiplatelet functions of clopidogrel or prasugrel in 31 healthy Japanese volunteers (14 CYP2C19 homo-extensive (homo-EMs), nine hetero-extensive (hetero-EMs), and eight poor metabolizers (PMs))...
September 5, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28845910/successful-eradication-of-helicobacter-pylori-with-a-herbal-medicine-goshuyuto-wu-zhu-yu-tang-plus-rabeprazole-after-failure-of-triplet-therapy-with-vonoprazan-a-report-of-three-cases
#20
Yutaka Nagata, Kazuhiko Nagasaka, Syunpei Koyama, Mai Murase, Minoru Saito, Toshinori Yazaki, Nobutoshi Komatsu, Takayuki Murase, Toshiki Uehara, Norihide Taniuchi
Vonoprazan, a potassium-competitive acid blocker, is used as a substitute drug for conventional proton pump inhibitors. Recently, vonoprazan has been applied for eradication of H. pylori (HP) infection, and the efficacies of vonoprazan-based triple therapy against HP infection have already been reported. However, treatment sometimes fails in the primary and/or secondary triplet eradication therapy, including with the use of vonoprazan for HP infection. We experienced three cases of refractory HP infection. They were treated with eradication therapy for HP infection with chronic gastritis...
August 28, 2017: Journal of Digestive Diseases
keyword
keyword
99659
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"